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Objective. Thyrotoxic periodic paralysis (TPP) is a potentially life-threatening complication of Graves’ disease (GD). The present
study compared the long-term efficacy of antithyroid drugs (ATD), radioactive iodine (RAI), and surgery in GD/TPP. Methods.
Sixteen patients with GD/TPP were followed over a 14-year period. ATD was generally prescribed upfront for 12–18 months before
RAI or surgery was considered. Outcomes such as thyrotoxic or TPP relapses were compared between the three modalities. Results.
Eight (50.0%) patients had ATD alone, 4 (25.0%) had RAI, and 4 (25.0%) had surgery as primary treatment. Despite being able
to withdraw ATD in all 8 patients for 37.5 (22–247) months, all subsequently developed thyrotoxic relapses and 4 (50.0%) had ≥1
TPP relapses. Of the four patients who had RAI, two (50%) developed thyrotoxic relapse after 12 and 29 months, respectively, and
two (50.0%) became hypothyroid. The median required RAI dose to render hypothyroidism was 550 (350–700) MBq. Of the 4
patients who underwent surgery, none developed relapses but all became hypothyroid. Conclusion. To minimize future relapses,
more definitive primary treatment such as RAI or surgery is preferred over ATD alone. If RAI is chosen over surgery, a higher dose
(>550MBq) is recommended.
1. Introduction
Thyrotoxic periodic paralysis (TPP) is a rare but potentially
life-threatening complication of thyrotoxicosis characterized
by muscle paralysis and serum hypokalemia due to massive
shifting of potassium into the intracellular space [1, 2]. The
overall incidence in Chinese and Japanese thyrotoxic patients
has been reported to be around 2% while in the West the
incidence is believed to be much lower (0.1-0.2%) [3–5].
Although any form of hyperthyroidism could potentially lead
to TPP, Graves’ disease (GD) is the most common cause
of TPP (GD/TPP) [6]. However, unlike GD which affects
mostly females, TPP predominantly occurs in males with the
male to female ratio ranging from 17 : 1 to 70 : 1 [6]. During
an acute attack of TPP with marked hypokalemia, cautious
potassium supplementation is of paramount importance as it
preventsmajor cardiopulmonary complications [6] but, at the
same time, one must bear in mind that overadministration
of potassium could lead to rebound hyperkalemia and fatal
dysrhythmia during recovery fromparalysis [7]. Nonselective
ß-adrenergic blockade has also been proposed as an alterna-
tive tomanage this acute phase and raise the serumpotassium
[6, 8]. Once this acute phase has been adequately dealt with,
the subsequent management of GD/TPP is mostly focused
on adequate control of hyperthyroidism because TPP usually
does not recur once euthyroidism has been attained [6].
Despite the availability of the recent guidelines [9], the
primary treatment of overt hyperthyroidism due to GD
remains controversial and varies significantly in different
parts of the world [6]. In our locality, the usual approach
for GD with/without TPP is to use antithyroid drug (ATD)
for approximately 12–18 months and then ATD is tapered or
discontinued once euthyroidism has been maintained [10].
More definitive treatmentmodalities such as 131I (radioactive
iodine or RAI) and surgery (in the form of total thyroidec-
tomy) are usually reserved for relapsed thyrotoxicosis after
a trial of ATD [10–12]. However, it remains unclear whether
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this approach or a more definitive upfront primary treatment
strategy is more appropriate for GD/TPP. To our knowledge,
few studies have specifically evaluated and compared the
efficacy and treatment outcomes between the three primary
treatment modalities (namely, ATD, RAI, and surgery) in
GD/TPP. Although a large series of GD/TPP patients was
reported recently, it did not specifically address this issue [13].
Thus this study aimed to evaluate and compare the efficacy
and treatment outcomes ofATD, RAI, and surgery as primary
treatment for GD/TPP by following the natural course of
patients.
2. Patients and Methods
Data for this study were retrieved from the established
Clinical Data Analysis and Reporting System or CDARS at
our institution. CDARS is an electronic system that prospec-
tively captures the diagnoses of all emergency admissions
at our institution from the year 2000 till now. Using this
database, 21 patients were retrospectively identified as having
GD/TPP. For the analysis, 5 (23.8%) patients were excluded
due to incomplete follow-up data.Therefore, 16 patients were
analyzed. On emergency admission, all 16 patients were con-
firmed to be biochemically thyrotoxic at the time of paralysis,
together with typical features of TPP which included history
of clinically flaccid weakness or paralysis, serum potassium
level <3.5mmol/L (normal: 3.6–5.0mmol/L), and thyrotoxi-
cosis confirmed by serum free T4 (FT4)> 23 pmol/L (normal:
12–23 pmol/L) on presentation. In addition to these criteria,
all patients with GD/TPP had to have a diffuse goiter with
either clinical ophthalmopathy and/or positive antimicroso-
mal and/or antithyroglobulin antibodies. Anti-TSH receptor
antibody (TRAb) and ultrasound (USG) were not routinely
performed. Furthermore, other causes of hypokalemic peri-
odic paralysis such as sporadic/familial hypokalemic periodic
paralysis, primary aldosteronism, and renal or intestinal loss
of potassium were excluded. Clinical and biochemical data
during the acute episode of GD/TPP attack prior to initiation
of potassium supplement including blood pressure, heart
rate, serum potassium, thyroid-stimulating hormone (TSH)
and FT4 levels, primary treatment modality, and subsequent
treatment outcomes such as thyrotoxic relapse, latest thy-
roid function status, and surgical-related complications were
recorded.
2.1. Treatment Principles of GD/TPP. Details of primary
treatment of GD were described previously [10]. In general,
as a primary treatment of GD with/without TPP, patients
were prescribed a course of ATDs (usually in the form of
carbimazole (CMZ) or propylthiouracil (PTU)) lasting for
a period of 12–18 months and then thereafter tapered or
stopped when thyroid function was normal. A great propor-
tion of GD would eventually go into prolonged remission
after ATDwithdrawal [11]. If there was evidence of thyrotoxic
relapse after a full course of ATDs, definitive treatment such
as RAI or total thyroidectomy was offered, depending on
goiter size and patient’s preference. Giving another course
of ATDs after a thyrotoxic relapse was an alternative if the
patient was not keen on or was contraindicated to RAI or
surgery.Those who underwent RAI or surgery were rendered
euthyroid by ATDs +/− Lugol’s solution before procedure.
After primary treatment, all patients were regularly followed
up for monitoring of thyroid function. The clinical course of
these patients was followed to the time of analysis. Follow-up
period was expressed in months and was calculated from the
diagnosis of GD (with or without TPP) to the latest follow-up.
All statistical analyses were performed using SPSS version
18.0 (SPSS, Inc., Chicago, IL, USA). Chi-square or Fisher’s
Exact test was used to compare categorical variables.
3. Results
Table 1 shows the demographic features of 16 TPP patients.
The median (range) age on presentation was 28 (17–45) years
old. There were 15 males and 1 female. The median (range)
body weight was 69.9 (45–105) kg. Among the cohort, 4
(25.0%) had family history of GD. Thirteen (81.2%) had
no previous history of thyroid disease and TPP was the
first presenting sign of thyrotoxicosis. Two (12.5%) had
associated Graves’ ophthalmopathy. These features were not
significantly different when comparing patients who received
ATD, RAI, or surgery as the primary treatment for GD/TPP.
Among our 16 patients, 8 (50.0%) had ATD, 4 (25.0%)
had RAI, and 4 (25.0%) had surgery as the primary treat-
ment for GD/TPP. There were 10 (62.5%) thyrotoxic recur-
rences. When comparing different treatment modalities, all
8 patients who received ATD had thyrotoxicosis recurrence
(100%), while 2 out of 4 (50%) in RAI group and 0% in the
surgery group had thyrotoxic relapse (𝑃 = 0.003). Regarding
the recurrence of TPP, the overall recurrence rate was 31% (5
patients) after primary treatment.
Table 2 summarizes the clinical and biochemical profiles
of the 16 patients on the presentation of GD/TPP. During
the acute attack of TPP, all patients presented bilateral lower
limb flaccid weaknesses, hypokalemia with serum potassium
of 2.5mmol/L (1.2–3.4) mmol/L, and thyrotoxicosis (TSH
0.03 (range: 0.01–0.18) mU/L and fT4 60.4 (range: 24.1–140)
ug/dL) (Table 2). All of them had normal body temperature
and pulse oximeter reading. Electrocardiographic changes
(T inversion in lead II to V) were found in 1 patient with
preexisting heart disease.Three (18.8%) patients had paralysis
upon waking up in early morning. Regarding precipitating
factors, TPP occurred after taking a heavy meal (𝑛 = 4) or
alcohol (𝑛 = 3). Other factors included acute upper respira-
tory infection (𝑛 = 2) and strenuous exercise (𝑛 = 1), while
7 patients had no specific triggers identified. None of these
patients had symptoms and signs involving respiratory sys-
tem and bulbar and ocular muscles during GD/TPP. Symp-
toms of TPP subsided spontaneously in 2 of our patients,
while the rest required potassium supplementation to reverse
muscle weakness. None of them were prescribed ß-blockers
at acute attack.
3.1. Details of Treatment Outcomes. Table 3 shows the
detailed clinical course of these 16 patients. The median
(range) follow-up period was 91.9 (11.2–293.2) months.
In the ATD group, all 8 patients completed their course
with a median duration of 19.5 (12–24) months. Although
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Table 1: A comparison of patient demographics and treatment outcome between patients who had antithyroid drugs (ATD), radioactive
iodine (RAI), and surgery as the primary treatment for Graves’ disease with thyrotoxic periodic paralysis (TPP).
Number (%)/median (range)
𝑃 value
Total (𝑛 = 16) ATD (𝑛 = 8) RAI (𝑛 = 4) Surgery (𝑛 = 4)
Gender (male : female) 15 : 1 8 : 0 4 : 0 3 : 1 0.202
Age (years) 28 (17–45) 26.0 (17–33) 36 (23–42) 30.5 (26–45) —
Smoker 10 (62.5%) 4 (50%) 2 (50%) 4 (100%) 0.202
Drinker 6 (37.5%) 2 (25%) 1 (25%) 3 (75%) 0.202
Body weight (kg) 69.9 (45.0–105) 70.9 (61–87) 66.5 (63–105) 74.5 (45–82) —
Family history of thyrotoxicosis 4 (25.0%) 1 (12.5%) 2 (50.0%) 1 (25%) 0.368
TPP as the initial thyrotoxicosis symptom 13 (81.3%) 5 (62.5%) 4 (100%) 4 (100%) 0.158
Presence of severe Graves’ ophthalmopathy∗ 2 (12.5%) 1 (12.5%) 0 (0.0%) 1 (25%) 0.565
Antithyroglobulin antibodies (<100 L/titre) 1088 (63–6400) 413 (63–1600) 3276 (100–6400) 81 (63–100) —
Antithyroid microsomal antibodies (<100 L/titre) 3325 (100–6400) 300 (100–400) 6400 (6400–6400) 3250 (100–6400) —
Outcome after primary treatment
Recurrence of thyrotoxicosis 10 (62.5%) 8 (100%) 2 (50%) 0 (0%) 0.003
Recurrence of TPP 4 (25.0%) 4 (50%) 0 (0%) 0 (0%) 0.069
Hypothyroidism requiring replacement 12 (75.0%) 6 (75.0%) 2 (50%) 4 (100%) 0.264
∗Although all patients had mild eye signs, only two patients had severe eye signs and required ophthalmic treatment for their eye condition.
Table 2: Clinical and biochemical profiles of the 16 patients on the
presentation of GD/TPP.
Number (%)/median (range)
Systolic blood pressure (mmHg) 131 (90–154)
Diastolic blood pressure (mmHg) 77 (69–99)
Heart rate (beats/min) 100 (66–138)
Body temperature (∘C) 37.0 (36.7–37.2)
TSH (normal: 0.35–4.78mIU/L) 0.03 (0.01–0.18)
Free T4 (normal: 12–23 pmol/L) 57.5 (24.1–140)
K+ (normal: 3.6–5.0mmol/L) 2.7 (1.2–3.4)
Precipitating/exacerbating factors
Heavy meals 4 (25.0%)
Alcohol intake 3 (18.8%)
Acute upper respiratory infection 2 (12.5%)
Strenuous exercise 1 (6.3%)
No factor identified 7 (43.8%)
TSH: thyroid stimulating hormone; K+: serum potassium.
these 8 patients were able to have ATD withdrawn for a
median duration of 37.5 (22–247) months, they all devel-
oped thyrotoxic relapses subsequently. Among these 8
patients, 4 (50.0%) patients suffered at least one further
attack of TPP during their thyrotoxic relapses (patients
2, 3, 6, and 7). Three patients with thyrotoxic relapses
eventually underwent total thyroidectomy (patients 1, 4,
and 8) while the other 3 required 2 courses of RAI to
render remission (patients 5, 6, and 7). In this group,
the median accumulative RAI dose to render hypothy-
roidism was 550 (500–700) MBq. All 3 patients required
daily thyroxine replacement. In the ATD group, 2 (25.0%)
patients (patients 2 and 3) remained hyperthyroid and were
on ATD on latest follow-up because they remained reluctant
to undergo RAI or surgery.
Of the four patients who received RAI as the primary
treatment (patients 9–12), two (50%) developed thyrotoxic
relapse in 12 and 29 months, respectively. The median first
RAI dose given was 325 (300–350) MBq while the median
accumulative RAI dose required to render hypothyroidism
was 550 (350–700) MBq. Of the two relapses after RAI, one
(patient 9) had a further 12-month course of ATD and subse-
quently remained euthyroid at the latest follow-up.The other
patient with thyrotoxic relapse received a further 300Mbq
RAI and was hypothyroid requiring thyroxine replacement at
the latest follow-up (patient 10). In summary, among the four
patients who received RAI as primary treatment, two (50.0%)
developed thyrotoxic relapse requiring further treatment and
2 (50.0%) developed hypothyroidism requiring thyroxine
replacement.
Table 4 shows the details of 7 patients with GD/TPP
who eventually underwent surgery. Of these 7 patients, 3
patients (patients 1, 4, and 8) were initially treated with
a trial of ATD before developing thyrotoxic relapse. Four
(25.0%) patients underwent total thyroidectomy as primary
treatment (patients 13–15). All patients recovered well after
total thyroidectomywithout the need for calcium+/− vitamin
D supplement. None of the patients had vocal cord paresis
as documented by postoperative laryngoscopy. All 7 patients
were placed on thyroxine replacement therapy with stable
thyroid function. None of them developed relapsed thyrotox-
icosis or TPP at the latest follow-up.
4. Discussion
TPP is a rare but potentially lethal complication of hyperthy-
roidism characterized by muscle paralysis and hypokalemia
[6]. Our series demonstrated the classical features of TPP
with the disease predominantly affecting young males of
Asian descent. Over 80% of our patients presented with
TPP as the first presenting symptom for thyrotoxicosis. This
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Table 3: A summary of the clinical course of the 16 patients with thyrotoxic periodic paralysis secondary to Graves’ disease (TPP/GD).
Patient
number
Sex/age
(years)
Primary
treatment
modality
Interval to first
thyrotoxic relapse
(months)
Treatment for
first thyrotoxic
relapse
Interval to second
thyrotoxic relapse
(months)
Treatment for
second thyrotoxic
relapse
Follow-
up
period
(months)
Thyroid function
status on latest
follow-up
1∗ M/31 ATD 22 ATD 25 Surgery 68.0 T4
2 M/33 ATD 76# ATD 20 ATD 124.8 Hyperthyroid
3∗ M/17 ATD 35# ATD 23† ATD 86.3 Hyperthyroid
4∗ M/25 ATD 40 ATD 52 Surgery 113.7 T4
5∗ M/32 ATD 28 RAI 250MBq 12 RAI 250MBq 154.3 T4
6 M/23 ATD 247# RAI 350MBq 6† RAI 350MBq 293.2 T4
7 M/27 ATD 102# RAI 250MBq 5† RAI 300MBq 146.1 T4
8∗ M/24 ATD 29 Surgery — — 66.0 T4
9∗ M/33 RAI 300MBq 29# ATD — — 87.3 Euthyroid
10∗ M/23 RAI 350MBq 12 RAI 300MBq — — 49.7 T4
11∗ M/39 RAI 300MBq — — — — 22.4 Euthyroid
12∗ M/42 RAI 350MBq — — — — 96.5 T4
13∗ M/45 Surgery — — — — 11.2 T4
14∗ F/26 Surgery — — — — 152.2 T4
15∗ M/32 Surgery — — — — 19.3 T4
16 M/39 Surgery — — — — 125.6 T4
GD/TPP: thyrotoxic periodic paralysis secondary to Graves’ disease; ATD: antithyroid drugs; RAI: 131I or radioactive iodine; T4: requiring daily thyroxine
replacement.
Note: the primary treatment of patient 7 was switched to PTU due to allergy to CMZ.
∗Where TPP was the first presenting symptom of thyrotoxicosis.
#Patient who had an attack of TPP during the first thyrotoxic relapse.
†Patient who had an attack of TPP during the second thyrotoxic relapse.
Table 4: Details of the 7 patients with thyrotoxic periodic paralysis who eventually underwent surgery/total thyroidectomy.
Patient
number
Sex/age
(years) Surgical indication
Number of
thyrotoxic
relapses before
surgery
Weight of
excised thyroid
gland (g)
Operating
time
(minutes)
Blood
loss
(mL)
Hospital
stay
(days)
RLN
injury
Postoperative
hypocalcemia
1 M/31 Patient preference 2 40 69 10 2 nil nil
4 M/25 Patient preference 2 86 151 200 2 nil nil
8 M/24 Patient preference 1 45 58 10 2 nil nil
13 M/45 Large goiter 0 125 273 300 3 nil nil
14 F/26 Patient preference 0 36 165 5 2 nil nil
15 M/32 Patient preference 0 33 90 3 2 nil nil
16 M/39 Large goiter 0 78 144 60 3 nil nil
RLN: recurrent laryngeal nerve.
highlights the importance of thinking about diagnosis of TPP
and assessing thyroid function in a young Asian male with
hypokalemic periodic flaccid paralysis [3–6].
One of the interesting findings from this observational
study was that despite the fact that the 8 patients with
GD/TPP were treated adequately with ATD for a median
duration of 19.5 months, all developed thyrotoxic relapse
after ATD withdrawal for a variable period of time. In the
literature, it is unclear what the actual thyrotoxic relapse rate
for GD/TPP treated with ATD is, but for GD in general (i.e.,
with or without TPP), the well-quoted figure for relapse after
ATD is 50–60% [12, 14]. Although the high relapse rate in
our study might be an overestimation as a result of selection
biases or small sample size, it seems that GD/TPP might
be less responsive to ATD alone when compared to GD
in general. It is possible that the occurrence of TPP may
signify a more severe entity of GD which is less likely to go
into remission with ATD alone. Of course this postulation
requires larger prospective studies to verify.
Another finding worth noting was that among the 8
patients who eventually relapsed after ATD, four (50%)
suffered another episode of paralysis. This TPP relapse rate
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appeared higher than a recent study which reported 29.6%
of patients had repeated TPP during withdrawal or tapering
of ATD [13]. However, this discrepancy might be due to the
difference in the length of follow-up between the two studies
as all of those on ATD were followed up for over 5 years (see
Table 3). Nevertheless, these data suggested that significant
proportion of thyrotoxic relapse in GD/TPP after treatment
by ATD would be complicated by TPP. Moreover, giving
repeated courses of ATD after ATD treatment failure did not
appear to be effective in achieving remission in GD/TPP. Two
patients (patients 2 and 3) remained hyperthyroid requiring
ATD after a follow-up period of 86.3 and 124.8 months,
respectively, while the rest ultimately required definitive
treatment. This observation therefore suggested that either
RAI or surgery might be a better primary treatment modality
thanATD to achieve remission and to prevent relapse forGD/
TPP in the long term.
However, it is worth noting that the relapse rate after
giving RAI was also high. Within the 7 patients who received
RAI for the first time (i.e., including those who relapsed with
ATD), 5 developed thyrotoxic relapses (patients 5, 6, 7, 9, and
10) and, of these, 3 had TPP during the relapse (patients 6, 7,
and 9). One possible reason for this high relapse ratemight be
related to the lowRAI dose used.Of the twopatients receiving
RAI 250MBq, all (100.0%) had thyrotoxic relapse while for
the three patients receiving RAI 350MBq, two out of three
(66.7%) had relapse. In this study, an accumulative RAI dose
≥500MBq would render patients permanently hypothyroid.
This finding appeared comparable to previous studies [15,
16]. Thus a higher dose of RAI should be considered to
achieve cure in GD/TPP [17] with an understanding that this
approach will most likely lead to permanent hypothyroidism
requiring T4 replacement. However since RAI could poten-
tially cause transient hyperthyroidism and perhaps early TPP
relapse [18], caution should be exercised when RAI is chosen
as definitive treatment. Perhaps, RAI should be avoided if a
patient has or is at risk of cardiovascular disease or significant
arrhythmias [18].
Since total thyroidectomy involves removal of almost all
thyroid tissue, it is expected that relapse would be rare. In our
experience, all 7 patients with GD/TPP who underwent total
thyroidectomy had an uneventful recovery with no signifi-
cant complications. Although all patients required life-long
thyroxine replacement after surgery, thyroid function was
easier to manage. Interestingly, rate of hypoparathyroidism
appeared comparatively lower in this group of patients [19].
Despite these findings, we would like to acknowledge
several shortcomings. Firstly, since this was a retrospective
analysis that relied on the accuracy of a prospectively col-
lected database, selection biases were inevitable. For example,
patients with thyrotoxic or TPP relapses might have been
more likely captured by the CDARS database than those
without relapses because the former would have hadmultiple
admissions and a greater chance of being captured by the
database. Moreover, some important data such as TRAb titre,
goiter volume by USG, and degree of ophthalmopathy were
not routinely checked in our center but could be significant
factors for disease relapses. Thirdly, despite a relatively long
study period, there were few patients eligible for analysis and
so this studymight have been underpowered to detect smaller
differences.
5. Conclusion
Patients with GD/TPP appeared to have a greater chance
of thyrotoxic and paralysis relapse when managed by ATD
alone. As a result, clinicians should consider more definitive
treatment such as surgery or RAI as the primary treatment
modality for patients with GD/TPP. If RAI is chosen over
surgery, a higher dose (>550MBq) should be used to mini-
mize future relapses with an understanding that permanent
hypothyroidism might be inevitable.
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